key: cord-0720341-avw928o4 authors: De Fenza, Maria; Esposito, Anna; D’Alonzo, Daniele; Guaragna, Annalisa title: Synthesis of Piperidine Nucleosides as Conformationally Restricted Immucillin Mimics date: 2021-03-16 journal: Molecules DOI: 10.3390/molecules26061652 sha: 237c510a42ffe6f7103c3782164a1f4e888d5c9f doc_id: 720341 cord_uid: avw928o4 The de novo synthesis of piperidine nucleosides from our homologating agent 5,6-dihydro-1,4-dithiin is herein reported. The structure and conformation of nucleosides were conceived to faithfully resemble the well-known nucleoside drugs Immucillins H and A in their bioactive conformation. NMR analysis of the synthesized compounds confirmed that they adopt an iminosugar conformation bearing the nucleobases and the hydroxyl groups in the appropriate orientation. The modulation of the activity of carbohydrate processing enzymes represents an important therapeutic target, given the involvement of these proteins in a plethora of metabolic events causing a variety of diverse pathologies [1] [2] [3] . Over the last decades, intense efforts have been focused on the identification of inhibitors or enhancers of such enzymes [1, [4] [5] [6] [7] with promising therapeutic applications for the treatment of viral infections [8, 9] , cancer [10] , diabetes [11] , tuberculosis, lysosomal storage diseases [12] , and parasitic protozoa [13] . An illustrative example in this area is represented by the class of iminosugars [4, 5, 7, 14] , glycomimetics (carbohydrate analogues) having the ring oxygen replaced by an amino group. Iminosugars are able to mimic the transition state of carbohydrate hydrolysis or transfer [15] (involving, in both cases, an upcoming glycosyl oxycarbenium cation), therefore interfering with the activity of carbohydrate-processing enzymes, such as glycosidases and glycosyltransferases [16] . Some among the most important examples of iminosugars include polyhydroxylated piperidines Miglitol, Miglustat, and Migalastat (Figure 1 ), which are FDA-approved drugs for the treatment of type 2 diabetes [17] , Gaucher [18] and Niemann-Pick type C [19] , and Fabry disease [20] , respectively. Piperidine iminosugars belonging to the unnatural L-series (L-iminosugars) also exhibit pharmacological properties, such as in the case of L-DGJ [21] , L-NBDNJ [22] (Figure 1 ), and its congeners [23, 24] . Similarly, iminosugars with a pyrrolidine skeleton (in both enantiomeric series) have been found to hold excellent glycomimetic properties, as in the case of naturally occurring Radicamine A and B [25] , 2,5-dideoxy-2,5-imino-D-mannitol (D-DMDP), 1,4-dideoxy-1,4-imino-D-arabinitol (D-DAB-1) (Figure 1 ), and their structurally related compounds [26, 27] . Polyhydroxylated pyrrolidine scaffolds can also be recognized in the structure of Immucillins, which are chemically stable 9-deazapurine C-nucleoside analogues endowed with a variety of therapeutic applications, ranging from the treatment of cancer and autoimmune disorders to parasitic and viral infections [28] . Immucillin-A (1, Imm-A, also known as BCX4430 or Galidesivir, Figure 2 ) has demonstrated to be active in in vivo models against a variety of RNA-dependent RNA polymerases (RdRp)-based pathogens, including Ebola, Marburg, Yellow Fever, and Zika viruses [29, 30] . The molecule has exerted a broad-spectrum activity in vitro against more than 20 RNA viruses belonging to nine different families, such as flaviviruses, filoviruses and also bunyaviruses, togaviruses, paramyxoviruses, coronaviruses, and arenaviruses [31] . Lately, clinical studies have been undertaken to explore the safety and antiviral properties of Galidesivir in patients with COVID-19 [32, 33] . On the other side, Immucillin H (2, Imm-H, also known as Forodesine or Mundesine, Figure 2 ), which is the result of a rational design process and has been at the core of intense kinetic investigations by Schramm et al., is a picomolar inhibitor of bovine and human purine nucleoside phosphorylases [34, 35] (PNP, E.C. 2.4.2.1). PNP is a ubiquitous nucleoside processing enzyme essential for DNA and RNA synthesis and it is involved in the reversible phosphorolysis of purine nucleosides to the corresponding bases and (deoxy)ribose-α-1-phosphate. Based on the observation that PNP inhibition stops the growth of activated T-cells, Immucillin-H has been identified as a key candidate for the treatment of leukemia and autoimmune diseases [36] . Over the last decades, further design endeavours have led to the identification of a new generation of Imm-H related PNP inhibitors, endowed with an even higher potency than the parent pyrrolidine nucleoside [37] . All these inhibitors shared an increase of conformational freedom degrees compared with Imm-H [37] . With the aim to provide an alternative strategy to PNP inhibitors, we conceived to replace the pyrrolidine scaffold with a conformationally more restricted biomimetic system. Our approach exploits the well-known finding that the quality of host-guest interactions benefits from the increase in the preorganization of the guest, since no entropy penalty is involved in the binding process. As demonstrative examples, conformationally restricted nucleosides bearing a sixmembered sugar unit have already been found to hold an excellent biomimetic potential in various therapeutic contexts [38, 39] , as a result of the resemblance of natural ribofuranosyl nucleosides in their bioactive conformations [40] . Accordingly, following our longstanding interest in the identification of conformationally restricted molecules with biomimetic properties [39, [41] [42] [43] [44] [45] [46] , we undertook the synthesis of novel Immucillin-A and Immucillin-H analogues, i.e., polyhydroxylated piperidine nucleosides 3 and 4 ( Figure 2 ). Our goal was to replace the five membered pyrrolidine scaffold of the drug candidates with a biomimetic six-membered unit. Indeed, among the two chair conformations that 3 and 4 are expected to be able to adopt, the 1 C 4 form mimics the bioactive 3 E conformation of Immucillins when bound to the PNP active site [37] . On this basis, this preliminary study is first aimed to tune up the synthetic path using natural nucleobases as model aglycones, in view of the synthesis of the congeners equipped with the more complex 9-deazapurine nucleobases. Indeed, differently from pyrrolidine nucleosides, move of the nucleobase from C1' to C2' in piperidine nucleosides, required for Immucillin biomimicry, allows to install natural nucleobases without affecting the structural integrity of the molecule. In addition, the analysis of the conformational preferences of 3 and 4 is herein performed to ascertain the biomimetic properties of this novel class of nucleoside analogues. The synthesis of nucleosides 3 and 4 was achieved from heterocyclic system 7, in turn obtained in a few steps by dithiin 5 and (R)-Garner aldehyde (6) (Scheme 1), using a similar synthetic sequence previously enabling the synthesis of unnatural L-iminosugars [22, 23, 47] . Deacetylation of 7 under Zemplén conditions (NaOMe, MeOH) quantitatively afforded 8 (96%), which was then treated with Raney ® -Ni in EtOH to cleave the dithioethylene bridge, yielding olefin 9 (76% yield). Stereoselective 4-OH-directed epoxidation of 9, using mCPBA in CH 2 Cl 2 led, as expected, exclusively to cis oxirane 10 (75% yield). In the subsequent ketalization step of OH groups in 10, we used an alternative procedure to the standard protocol (PTSA, 2,2-dimethoxypropane, 2-methoxypropene) [48] , in order to avoid strictly anhydrous conditions, which are typically required to limit by-product formation derived from acid-catalysed oxirane ring opening. Exploiting our longstanding expertise in the field [23, [49] [50] [51] [52] [53] , we chose the procedure involving the use of polymersupported triphenyl phosphine (PS-TPP)/I 2 /imidazole (ImH) system as the activating agent for the protection reaction, using acetone as the acetonide source. In this case, the reaction involves the activation of acetone by the triphenylphosphonium iodide and the subsequent double attack by the diol to the activated ketone. Challenging for our synthetic target, PS-TPP/I 2 /ImH is also reported to enable epoxide ring opening, to provide the corresponding iodohydrins [54] . However, in our hands, the addition of 10 to a suspension of the premixed activating agent in the anhydrous acetone provided, already after 1 h at room temperature, the corresponding 4',6'-O-isopropylidene derivative 11 with no traces of other byproducts. The pure ketal 11 could be isolated after a simple filtration of the reaction mixture, increasing the synthetic benefits of the procedure. With the fully protected epoxide 11 in hand, piperidine nucleosides were eventually obtained, as already reported for similar substrates [42] . By virtue of the locked conformation of compound 11, the treatment of the latter with DBU and adenine in anhydrous DMF at 120 • C (Scheme 2) only led to the epoxide ring opening by the nucleobase at the desired C2 axial position, affording regioselectively the corresponding protected altritollike nucleoside 12, additionally in a very good yield (86%). Under the same coupling conditions, the treatment of 11 with 6-chloropurine provided a mixture of chloropurine and hypoxanthine-containing nucleosides 13 (82%) and 14 (18%), respectively. Alternatively, the same reaction carried out replacing DBU with NaH in DMF at room temperature yielded 6-chloropurine nucleoside as the only observed product. The quantitative conversion of 13 into 14 could be then obtained by the treatment with a refluxing 0.5 M NaOH solution, while the corresponding adenosine derivative 12 could be obtained by the treatment of 13 with conc. NH 4 OH at reflux temperature. Eventually, the subsequent addition of 2 M HCl to crude nucleosides 12 and 14 allowed both isopropylidene and Boc groups removal, providing the corresponding nucleosides 3 and 4 as HCl salts (3: > 99% from 12; 4: 84% from 13). The NMR analysis of nucleosides 3 and 4 confirmed the formation of N9-C2' bonds, as revealed by HMBC correlations between H-2' of the piperidine and the C-4 of purines. Furthermore, 1D and 2D spectra strongly suggested that the desired conformations with equatorially oriented nucleobases were adopted by both nucleosides (Figure 3 ). Indeed, 1 The observed piperidine conformation is opposite to the 4 C 1 form (axially oriented nucleobase) adopted by altro-configured nucleosides having a ring oxygen and more generally by the majority of biomimetic hexitol nucleosides [40, 55] . Conversely, the conformation of 3 and 4 is in line with those adopted by cyclohexanyl nucleosides, having a methylene group in place of ring heteroatom [42, 56] . In agreement with previous studies on both hexitol and cyclohexanyl nucleosides [56] , it is conceivable to hypothesize that the conformation of piperidine nucleosides is adopted to relieve the 1,3-diaxial strains involving the nucleobase and hydrogen atoms from C4 and the protonated amino group in the 4 C 1 conformer (Figure 3) . Having equatorially oriented nucleobases, nucleosides 3 and 4 hold the conformational requirements to mimic the 3 E pyrrolidine ring puckering of Immucillins H and A. Based on these data, the piperidine core can be therefore considered as an appropriate scaffold for the construction of preorganized Immucillin analogues. All chemicals and solvents were purchased with the highest degree of purity (Sigma-Aldrich, Darmstadt, Germany; Alfa Aesar, Karlsruhe, Germany; VWR, Milan, Italy) and used without further purification. The reactions were monitored by TLC (precoated silica gel plate F254, Merck, Darmstadt, Germany) and the products were detected by exposure to ultraviolet radiation, iodine vapor, and chromic mixture. Column chromatography: Merck Kieselgel 60 (70-230 mesh). The purity of compounds was determined by CHNS analysis and was ≥ 95% in all cases. NMR spectra were acquired on NMR spectrometers Bicyclic Compound 8. MeONa (16 mg, 0.30 mmol) was added to a stirring solution of 7 [47] (0.12 g, 0.30 mmol) in MeOH (2.0 mL). The mixture was stirred for 4 h at room temperature and then neutralized with a few drops of acetic acid. Then, solvent removal under reduced pressure and chromatography of the crude residue over silica gel (hexane/EtOAc = 6/4) provided pure 2 (92 mg, 96% yield) as a colorless oil. [ To a suspension of Raney-Ni (W2) (0.90 g, wet) in EtOH (1 mL) a solution of bicycle piperidine 8 (90 mg, 0.28 mmol) in the same solvent (3 mL) at 0 • C was added. The suspension was stirred for 2 h at room temperature, then the solid was filtered off and washed with EtOH. The filtrate was concentrated under reduced pressure providing the crude residue whose chromatography over silica gel (hexane/acetone = 6/4) gave pure 9 (49 mg, 76% yield) as a colorless oil. [α] 25 D + 87.8 (c 0.85, CHCl 3 ). NMR data for 9 were consistent with those reported elsewhere [57] . Anal. calcd for C 11 Hypoxanthine analogue 4. Nucleoside 13 (15 mg, 0.03 mmol) was refluxed for 2 h in a 0.5 N aq NaOH (0.5 mL). Then, the reaction mixture was cooled to 0 • C and 0.5 N HCl was carefully added (0.8 mL). The solution was evaporated under reduced pressure. The crude was then dissolved in THF (0.2 mL) and then 2 M HCl (0.5 mL) was added. The reaction mixture was heated to reflux temperature for 3 h. Then, the solvent was evaporated under reduced pressure and the subsequent trituration of the solid with Et 2 O gave pure 4 as hydrochloride salt (8.0 mg, 84%). 13 The synthesis of piperidine nucleosides 3 and 4, acting as conformationally restricted analogues of Immucillins H and A, has been herein reported. Our approach exploits our consolidated strategy, involving the synthetic manipulation of coupling product 7 starting from our three-carbon homologating agent 5. The stereoselective preparation of cis epoxide 11 and the subsequent coupling reaction in two alternative approaches with model nucleobases have enabled access to piperidine nucleosides 3 and 4 with the desired D-altro configuration. NMR analysis demonstrated that both compounds resemble the bioactive conformation of Immucillins H and A, as they adopt iminosugar conformations with equatorially oriented nucleobases. Further studies will be devoted to explore the suitability of our approach to introduce a variety of other heterocyclic bases for SAR analysis. Particularly, synthetic studies aimed to incorporate Immucillin-mimicking 9-deazapurine nucleobases and in vitro assays, aimed to ascertain the pharmacological potential of all the synthesised nucleosides, are currently ongoing and will be published elsewhere. Supplementary Materials: Figure S1 : 1H and 13C NMR spectra of compound 8; Figure S2 : 1H and 13C NMR spectra of compound 10; Figure S3 : 1H and 13C spectra of compound 11; Figure S4 : 1H and 13C NMR spectra of compound 12; Figure S5 : 1H and 13C NMR spectra of compound 13; Figure S6 : 1H and 13C NMR spectra of compound 3; Figure The authors declare no conflict of interest. Developing inhibitors of glycan processing enzymes as tools for enabling glycobiology Carbohydrate-processing enzymes of the lysosome: Diseases caused by misfolded mutants and sugar mimetics as correcting pharmacological chaperones From Synthesis to Therapeutic Applications Iminosugars past, present and future: Medicines for tomorrow High-Throughput approaches in carbohydrate-active enzymology: Glycosidase and glycosyl transferase inhibitors, evolution, and discovery Iminosugars as therapeutic agents: Recent advances and promising trends Iminosugar antivirals: The therapeutic sweet spot Iminosugars: A host-targeted approach to combat Flaviviridae infections Natural and synthetic iminosugars as carbohydrate processing enzyme inhibitors for cancer therapy Mini-special issue paper management of diabetic patients with hypoglycemic agents α-glucosidase inhibitors and their use in clinical practice Lysosomal storage diseases Plasmodium purine metabolism and its inhibition by nucleoside and nucleotide analogues Glycomimetics at the mirror: Medicinal chemistry of L-iminosugars Glycosidase inhibition: Assessing mimicry of the transition state Iminosugars as Glycosidase Inhibitors Pharmacotherapeutics of miglitol: An α-glucosidase inhibitor Miglustat (Zavesca ® ) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme Treatment outcomes following continuous miglustat therapy in patients with Niemann-Pick disease Type C: A final report of the NPC Registry Switch from enzyme replacement therapy to oral chaperone migalastat for treating Fabry disease: Real-life data Looking-glass synergistic pharmacological chaperones: DGJ and L-DGJ from the enantiomers of tagatose Synthesis of an allosteric enhancer of α-glucosidase activity for the treatment of Pompe disease Exploring the effect of chirality on the therapeutic potential of N-alkyl-deoxyiminosugars: Anti-inflammatory response to Pseudomonas aeruginosa infections for application in CF lung disease Synthesis and therapeutic applications of iminosugars in cystic fibrosis Two new pyrrolidine alkaloids, radicamines A and B, as inhibitors of alpha-glucosidase from lobelia chinensis lour 1,4-Dideoxy-1,4-imino-D-arabinitol (DAB) analogues possessing a hydrazide imide moiety as potent and selective α-mannosidase inhibitors Nitrogen-in-the-ring pyranoses and furanoses: Structural basis of inhibition of mammalian glycosidases The immucillins: Design, synthesis and application of transition-state analogues Immucillins in infectious diseases A direct-acting antiviral drug abrogates viremia in Zika virus-infected rhesus macaques Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430 Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19 Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes The transition to magic bullets-transition state analogue drug design A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine) Four generations of transition-state analogues for human purine nucleoside phosphorylase Evaluation of anhydrohexitol nucleic acid, cyclohexenyl nucleic acid and D-altritol nucleic acid-modified 2 -O-methyl RNA mixmer antisense oligonucleotides for exon skipping in vitro Structureactivity relationship study of a potent α-thrombin binding aptamer incorporating hexitol nucleotides Nucleic acids with a six-membered 'carbohydrate' mimic in the backbone Enantiomeric selection properties of β-homoDNA: Enhanced pairing for heterochiral complexes Oligonucleotides containing a ribo-configured cyclohexanyl nucleoside: Probing the role of sugar conformation in base pairing selectivity A. 1 ,5 -Anhydro-L-ribo-hexitol adenine nucleic acids (α-L-HNA-A): Synthesis and chiral selection properties in the mirror image world A stereoconvergent Tsuji-Trost reaction in the synthesis of cyclohexenyl nucleosides Synthesis of N-1 and ribose modified inosine analogues on solid support Synthesis of 4-N-alkyl and ribose-modified AICAR analogues on solid support A general approach to the synthesis of 1-deoxy-L-iminosugars The chemistry of the 1-deoxynojirimycin system. Synthesis of 2-acetamido-1,2-dideoxynojirimycin from 1-deoxynojirimycin Triphenylphosphine polymer-bound/iodine complex: A suitable reagent for the preparation of O-isopropylidene sugar derivatives Synthesis and proteomic activity evaluation of a new isotope-coded affinity tagging (ICAT) reagent Expeditious synthesis and preliminary antimicrobial activity of deflazacort and its precursors N-Nonyloxypentyl-L-deoxynojirimycin inhibits growth, biofilm formation and virulence factors expression of Staphylococcus aureus Toward the identification of novel antimicrobial agents: One-pot synthesis of lipophilic conjugates of N-alkyl D-and L-iminosugars Polymer-supported triphenylphosphine: Application in organic synthesis and organometallic reactions Exploring the role of chirality in nucleic acid recognition Synthesis and pairing properties of oligonucleotides containing 3-hydroxy-4-hydroxymethyl-1-cyclohexanyl nucleosides Stereoselective synthesis of L-deoxyaltronojirimycin from L-serine